




EQUITY RAISING PRESENTATION



AVEXA

IMPORTANT NOTICE AND DISCLAIMER

This investor presentation (Presentation) has been prepared by Avexa Limited (Avexa) in relation to an accelerated pro rata non-renounceable entitlement issue (Rights Issue) and placement to institutional investors (Placement), (collectively, the Offer). The Rights Issue and the Placement will take place under sections 708AA and 708 (respectively) of the Corporations Act 2001 (Cth) (Corporations Act) as modified by Australian Securities and Investments Commission (ASIC) Class Order 08/35 (CO 08/35).

In accepting this Presentation, you acknowledge and agree to be bound by the following terms and conditions.

Summary information

This Presentation contains summary information about Avexa and is dated 2 November 2015. The information in this Presentation is of general background and does not purport to summarise all information that an investor should consider when making an investment decision. It should be read in conjunction with Avexa's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (ASX), which are available at www.asx.com.au or www.avexa.com.au

Not investment advice

This Presentation is for information purposes only and is not financial product or investment advice or a recommendation to acquire entitlements or shares.

This Presentation is not a prospectus or a product disclosure statement under the Corporations Act nor is it an offering document under any other law, and has not been lodged with ASIC.

The information in this Presentation has been prepared without taking into account the investment objectives, financial circumstances, taxation position or particular needs of investors. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek appropriate legal, financial and taxation advice appropriate to their jurisdiction. Cooling-off rights do not apply to the acquisition of shares in Avexa.

Investment Risk

An investment in Avexa shares is subject to known and unknown risks, some of which are beyond the control of Avexa. Avexa does not guarantee any particular rate of return or the performance of Avexa. Investors should read the 'Key Risks' section in the Presentation for a non-exhaustive summary of the key issues that may affect Avexa and its financial and operating performance.

Foreign jurisdictions and selling restrictions

This Presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any place in which, or to any person to whom, it would not be lawful to make such an offer.

The information in this Presentation has been prepared to comply with the requirements of the securities laws of Australia. No action has been taken to register or qualify the Rights Issue, the entitlements or the shares, or otherwise permit the public offering of the shares, in any jurisdiction outside of Australia. Any non-compliance with these restrictions may contravene applicable securities laws.

Not for distribution in the United States

This Presentation may not be released or distributed in the United States. This Presentation does not constitute an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, any securities in the United States or to any person that is, or is acting for the account or benefit of a 'U.S. person' (as defined in Regulation S under the United States Securities Act of 1993 (Securities Act)) (U.S. Person), or in any other jurisdiction in which such an offer would be illegal. The shares referred to in this presentation may not be offered in the United States, or to or for the account or benefit of any U.S. Person (or to any person acting for the account or benefit of a U.S. Person).

Disclaimer

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this Presentation. To the maximum extent permitted by law, none of Avexa, Novus Capital Limited (Novus) or any of their respective related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors (collectively, Related Parties), nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this Presentation.

To the fullest extent permitted by law, Avexa, Novus, and each of their respective Related Parties:

- A. do not accept any responsibility for any interpretation that any recipient or any other person may place on this Presentation or for any opinion or conclusion that any recipient or any other person may form as a result of examining the information contained in this Presentation; and
- B. do not accept any liability, whether direct or indirect or consequential, for any loss, damage, cost, expense, outgoing, interest, loss of profits or loss of any kind (Losses) suffered or incurred by any person (whether foreseeable or not) as a result of or by reason of or in connection with the provision or use of information contained (or not contained) in this Presentation, or of any recipient or its representatives or advisers acting on or relying on any information provided or referred to in or omitted from this Presentation or any other written or oral opinions, whether the Losses arise in connection with any negligence, default or lack of care on the part of Avexa, Novus, and each of their respective Related Parties or any other cause.

Any recipient of this presentation acknowledges and agrees that:

- A. they will rely entirely upon their own assessment and advice in relation to the business, assets, financial position and affairs of Avexa, including conducting independent inquiries, due diligence or analysis with appropriate legal, financial, taxation and other advice, as required;
- B. any opinions expressed in this presentation are based on the knowledge and approach of the persons forming the opinion at the date that the opinion was formed and may have ceased or may in the future cease to be appropriate in the light of subsequent knowledge or attitudes; and
- C. neither Novus, nor any of their affiliates, nor any of their respective related bodies corporate, directors, officers, partners, employees and agents:
 - i. have caused or authorised the issue, submission, dispatch or provision of this Presentation, nor do they make any recommendation as to whether any potential investor should participate in the Offer
 - ii. makes or purports to make any statement in this Presentation;
 - iii. accepts any fiduciary obligation to or relationship with any investor or potential investor in connection with the proposed Offer or otherwise.


Forward looking statements This Presentation contains "forward-looking" statements. Forward looking words such as, "expect", "anticipate", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" and other similar expressions are intended to identify forward-looking statements.

Forward-looking statements, opinions and estimates provided in this Presentation are based on estimates and assumptions related to future business, economic, market, political, social and other conditions that, while considered reasonable by Avexa, are inherently subject to significant uncertainties and contingencies. Many known and unknown factors could cause actual events or results to differ materially from estimated or anticipated events or results reflected in such forward-looking statements. Such factors include, but are not limited to: operating and development risks, economic risks and a number of other risks and also include unanticipated and unusual events, many of which are beyond Avexa's ability to control or predict. The forward-looking statements only speak as at the date of this Presentation and, other than as required by laws, Avexa, Novus and their respective Related Parties disclaim any duty to update forward looking statements to reflect new developments.

To the maximum extent permitted by applicable laws, Avexa, Novus and their respective Related Parties make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this Presentation.



AVEXA



Novus
Capital

AFS Licence No: 238168



EXECUTIVE SUMMARY

- ▶ Avexa Limited (ASX Code: AVX) (**Avexa**) is undertaking an equity raising up to \$4.0 million to fund the development and commercialisation of the advanced technology acquired from TALI Health Pty Ltd (**TALI**).
 - ▶ Issue Price of \$0.16
 - ▶ Price calculated to reflect the proposed 20:1 consolidation.
- ▶ The Equity Raising comprises:
 - ▶ Up to \$4.0 million placement to Institutional and Sophisticated Investors (**Placement**).
- ▶ The proceeds of the Placement will be used to fund the further commercialisation of the TALI technology via the following:
 - ▶ Planning for Development and Trial Phases;
 - ▶ Product Development;
 - ▶ Testing, Validation, Clinical Trial Support & Data Analysis; and
 - ▶ Provision for Clinical Support.



COMPANY OVERVIEW

- ▶ Avexa is a Biotechnology Company dedicated to the discovery and development of new drugs to treat serious infectious diseases, particularly Human Immunodeficiency Virus (HIV). Owing to the propensity of viruses and bacteria to become resistant to existing drugs, there is a constant need for new drugs to treat patients who have failed existing standard treatments. We focus on applying our expertise in these specialist, high value areas where the therapeutic need is greatest.
- ▶ Avexa's lead project is Apricitabine (ATC), a new treatment for drug resistant HIV infection. ATC has proven clinical activity through numerous clinical trials and is in the last stage of development prior to approval. Our HIV integrase project is at an earlier stage of development, but shows great promise as a once daily integrase inhibitor for integrase-resistant HIV. Our antibiotic project focusses on developing drugs against antibiotic-resistant bacterial infections, widely recognised as an emerging and serious threat to public health.
- ▶ Any further clinical development on Avexa's late and early stage drug portfolio is awaiting investment returns from the investment in Coal Holdings USA; meanwhile, the Directors have been actively searching for a healthcare business undertaking that fits strict criteria including the prospect of near term returns for shareholders.



NEW OPPORTUNITY FOR AVEXA


- ▶ On the 12th October 2015 Avexa Limited announced it had entered into a binding Implementation Deed with TALI Health Pty Ltd (TALI) to acquire all of the ordinary voting shares in TALI in exchange for the issue to TALI shareholders of fully paid ordinary shares in Avexa.
- ▶ TALI has the exclusive global license to the TALI Technology which underpins TALI's revolutionary and innovative cognitive function approach to diagnosing and treating developmental disabilities, including Autism, in modern society.
- ▶ The transaction is conditional on several matters including all TALI shareholders accepting the Avexa offer and satisfactory completion of the private placement as well as Avexa shareholder approval of the transaction by ordinary resolutions, including approval of issue of shares to TALI shareholders and under the private placement.
- ▶ A private placement of up to \$4.0 million to sophisticated and professional investors is proposed to be undertaken by Avexa upon closing of the proposed transaction (subject to shareholder approval).





ABOUT TALI

- ▶ TALI Health has the exclusive global license to the TALI Technology together with the option to acquire the TALI Technology outright.
- ▶ TALI is seeking to position itself as the global leader in the diagnosis and treatment of children with intellectual disabilities, via the unique cognitive abilities focused on in the TALI Process.
- ▶ The TALI Process is a result of ground-breaking research pioneered over twenty years by internationally renowned Professor Kim Cornish, Head of School of Psychological Sciences at Monash University and her team.
- ▶ A collaboration between Monash University, Grey Innovation Pty Ltd and Torus Games Pty Ltd, together developed the solution in response to the absence of holistic approaches in addressing the limited awareness and treatment of intellectual disabilities, including Autism, in modern society.
- ▶ The front end of the TALI Process is an attention measuring and training game (accessed by downloading an "App") for delivering interventions on tablets (or similar). The back end of the TALI Process is a Cloud based, centralised secure data collection, analysis and report back function.



 MONASH University

GREY INNOVATION
TECHNOLOGY COMMERCIALISATION



A V E X A

Novus
Capital

AFS Licence No: 238168



TALI TECHNOLOGY


- ▶ Unlike other technology, the TALI Technology recognises that not all children with Developmental Delay (DD) will have the same degree or type of attention difficulty.
- ▶ In some children, the ability to remain focused on a given task may be especially weak but other attention skills, such as selection of salient information may be less vulnerable to impairment. These relative strengths, once identified, can be used to improve and build up the weaker attention skills and also improve cognitive functions related to working memory, literacy and numeracy.
- ▶ By avoiding a “one-size-fits all” approach to intervention which is neither satisfactory nor likely to produce a sustained long-term improvement in attention functions, the TALI Technology enables intervention uniquely designed for children with DD. In addition, the TALI program is sensitive in distinguishing between age related changes in attention skills.





TALI TECHNOLOGY (cont.)


- ▶ The TALI Technology is accessed by downloading an “App” from the internet via everyday electronic devices (e.g. tablet, computer, etc.) making the TALI Technology portable and able to be used at home or school as well as accessible to children in metropolitan and rural regions, particularly areas that often cannot access intervention services which are located predominantly in metropolitan regions.
- ▶ The back end of the TALI Process is a powerful computer program that collects and analyses data each time a patient plays one of the computer games.
- ▶ The analysis of this data is used to prepare reports for clinical professionals, teachers and parents to use for diagnostic and therapeutic purposes and then to monitor the progress of their patients, and, where necessary, adjust the treatment.





BENEFITS OF TALI TECHNOLOGY





- ▶ More accurate measurement – measurements made thousands of times each gameplay;
- ▶ More frequent assessment – TALI can be used several times each day;
- ▶ Not subjective – a repeatable accurate measurement;
- ▶ Results stored – can return to results and observe changes in level of cognitive ability to measure effects of interventions and medications;
- ▶ Scientifically validated- designed by researchers, tested in a randomised controlled trial by Monash University;
- ▶ Ongoing scientific analysis and development by Monash University- Institute for Cognitive and Clinical Neurosciences (ICCN)
- ▶ Convenience – can be used in the home; and
- ▶ Simple billing model- (e.g.) report cost integrated into clinician fee.





TALI – CLINICAL TRIAL FINDINGS


- ▶ A double blind randomised controlled trial was conducted comprising 76 children aged 4 to 11 years with developmental disabilities (IQ<75).
- ▶ The trial assessed whether children who used the TALI program for 20 minutes, five days a week over a five week period, showed greater benefits in attention and academic outcomes than children in a control group
- ▶ Core findings revealed general improvements in the attention training group on most outcome measures.





TALI – CLINICAL TRIAL FINDINGS (cont.)

- ▶ Training specific effects were observed in selective attention and numeracy skills. E.g. children who used the TALI program improved significantly more than children in the control program
- ▶ These results provide the first indication that a relatively short but intensive intervention can lead to improvements in aspects of attention which can transfer to learning in children with developmental disabilities.





EQUITY RAISING

► Offer Overview

- A Placement to professional and sophisticated investors will seek to raise up to \$4.0 million at an issue price of \$0.16 per share (after taking into account the proposed 20:1 consolidation).
- This Placement will be subject to shareholder approval at the Annual General Meeting scheduled for Thursday 26th November 2015.
- The funds raised in this Placement will be applied towards product development, Torus Games enhancements, clinical trials and workshops and initial rollout in targeted centres of TALI.



USE OF FUNDS

Description	Amount
Planning for Development and Trial Phases	\$225,000
Product Development	\$1,710,000
Testing, Validation, Clinical Trial Support & Data Analysis	\$460,000
Provision for Clinical Support	\$350,000
Marketing & Advertising	\$800,000
Working Capital	\$455,000
TOTAL	\$4,000,000



EQUITY RAISING INDICATIVE TIMETABLE

Event	Date
Placement Offer Opens	9 th November 2015
Placement Offer Closes	25 th November 2015
Quotation of new shares issued under Placement	2 nd December 2015



CONTACT



Iain Kirkwood
Avexa Limited
Ph: +61(0) 408 473 496
E: iain@sandringham.com.au



Benjamin Yeo
Novus Capital Limited
Ph: +61(0)3 8602 1713
E: ben.yeo@novuscapital.com.au